PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$52.13 USD
+0.02 (0.04%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $53.00 +0.87 (1.67%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PTCT 52.13 +0.02(0.04%)
Will PTCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTCT
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Other News for PTCT
SA analyst upgrades/downgrades: AMD, TSLA, SHEL, PTCT
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
PTC Therapeutics: Uncertainty Abounds Ahead Of Q2 Earnings - I'm Upgrading To 'Hold'
PTCT Price Target Raised to $86 by Truist Securities | PTCT Stock News
PTC Therapeutics (PTCT) Sees Raised Price Target by B of A Securities | PTCT Stock News